Re: GRAS Notice No. GRN 000866

Dear Mr. Drozen:

The Food and Drug Administration (FDA, we) is granting your request on behalf of Amano Enzyme, Inc. (Amano) to cease our evaluation of GRN 000866, which we filed on August 1, 2019. We received your request to cease to evaluate the notice on January 13, 2020.

The subject of the notice is acylglycerol lipase enzyme preparation produced by a genetically engineered Penicillium camemberti overexpressing the acylglycerol lipase gene (acylglycerol lipase enzyme preparation). You stated that the acylglycerol lipase enzyme preparation is intended for use as an enzyme in dairy, fats, and oil processing at up to 2522 mg Total Organic Solids (TOS)/kg raw material. The notice informs us of Amano's view that the uses of acylglycerol lipase enzyme preparation are GRAS through scientific procedures.

Upon review of your submission we informed you via a teleconference on October 30, 2019, that your GRAS notice included data supporting two acylglycerol lipase enzyme preparations. They are:

1. Acylglycerol lipase enzyme preparation produced by P. camemberti and

In the teleconference, FDA discussed that a GRAS notice is designed to describe the safety of uses of a single ingredient. Therefore, we offered you the opportunity to request that we cease our evaluation of GRN 000866. In an email dated January 13, 2020, you requested on behalf of Amano that we cease our evaluation of GRN 000866 and noted that you will submit a separate GRAS notice for the use of each enzyme preparation.
In accordance with 21 CFR 170.275(b)(3), the text of this letter responding to GRN 000866 is accessible to the public at www.fda.gov/grasnoticeinventory.

Sincerely,

Susan J. Carlson
Director
Division of Food Ingredients
Office of Food Additive Safety
Center for Food Safety
and Applied Nutrition

Digitally signed by Susan J. Carlson
Date: 2020.02.05 14:45:24 -05'00'